Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Regulatory News (BYOT)

  • There is currently no data for BYOT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition of ByoFresh

4 Feb 2010 09:42

RNS Number : 6801G
Byotrol PLC
04 February 2010
 



 

4 February 2010

 

Byotrol plc

ByoFresh acquisition

 

The Board of Byotrol plc ('Byotrol' or the 'Company'), the leading anti-microbial hygiene company, is pleased to announce the acquisition of the business and certain assets of Byofresh Limited (ByoFresh).

 

ByoFresh is a specialist pet care product business supplying an extensive range of pet grooming and hygiene products to professional and domestic customers, both through direct sale and through retailers. In 2006 ByoFresh became an early adopter of Byotrol's technology and has since been recognised for the quality and effectiveness of its products by industry experts, including being awarded 'Glee Pet Index Highly Commended New Product Of The Year 2006' and 'Pets At Home Supplier Best New Product 2007.'

 

Paul Foden, Managing Director of ByoFresh, qualified as a Chartered Accountant with Arthur Andersen before joining their management consultancy arm Accenture. Since leaving Accenture Mr Foden has spent the last six years building ByoFresh into a successful supplier of pet products.

 

The ByoFresh business is a good strategic fit to Byotrol's stated strategy of selling Byotrol based products through specialist distributors into niche markets. The global pet care products market is estimated at £12 billion annually.

 

Having shown success in the UK markets, ByoFresh will benefit significantly from the additional resources and industry contacts available at Byotrol. Byotrol will add a worldwide marketing capability to the ByoFresh product range which will accelerate the distribution capability considerably.

 

The unaudited results for ByoFresh for the year ended 30 June 2009 show turnover of £0.657m compared to £0.369m in the year ended 30 June 2008, with gross profit of £0.158m and £0.140m respectively. Operating loss for 2009 was £(0.092)m and £(0.036)m in 2008, resulting in respective operating margins of (13.98)% and (9.78)%. It is anticipated that ByoFresh will make a positive contribution in the next financial year.

 

The consideration for the acquisition will be satisfied, at completion, by the issue of 400,000 ordinary shares in Byotrol. In addition, an anticipated £31,008 will be paid for certain acquired fixed assets. The modest additional cash requirement incurred in the current financial year following the acquisition will be covered by the payment received from the recently announced US option agreement announced on 21 December 2009. The Company has entered into a service contract with Mr Foden which will permit him, subject to certain profit and revenue targets, to earn bonuses of up to a maximum, in aggregate, £1.75 million, which will only be achieved if ByoFresh achieves a significant uplift in performance both against historic measures and the Board's forecasts in the three years following completion. Payment will be made in shares and/or cash at the Company's election.

 

Application will be made to the London Stock Exchange for the new ordinary shares to be admitted to trading on AIM. It is expected that Admission will become effective and that trading in the new ordinary shares will commence on AIM at 8.00 a.m. on 10 February 2010. Following the issue of these shares, the Company will have 84,116,411 ordinary shares in issue each share holding one voting right.

 

The new ordinary shares will, when issued and fully paid, rank pari passu in all respects with the existing ordinary shares, including the right to receive any dividend or other distribution declared, made or paid after the date of their unconditional allotment.

 

David McRobbie, Chief Executive of Byotrol, commented:

 

"We have been working closely with ByoFresh for a number of years and have established the significant potential for ByoFresh in the pet care market. 

 

"The pet care industry's recognition of the superior performance and long lasting effectiveness of ByoFresh products is a valuable endorsement. We at Byotrol are keen to ensure that we maximise the opportunity in that market for Byotrol based products."

 

Enquiries:

 

David McRobbie, Chief Executive 0161 277 9518

Stephen Falder, Deputy Chairman

Richard Bell, Finance Director

Byotrol plc

 

Russell Cook / Carl Holmes 020 7149 6000

Charles Stanley Securities

Nominated Adviser

 

Tom Cooper / Paul Vann 020 3043 4162

Winningtons 0797 122 1972

 

Notes to Editors:

 

Byotrol Plc (BYOT.L), quoted on AIM, is a leading microbial technology hygiene company, operating globally in the Health, Food, Leisure, Consumer, Industrial and Agriculture sectors, providing a low toxicity product with a broad-based and long lasting efficacy across all microbial classes; bacteria, viruses, fungi, moulds, microbacteria and algae.

 

The Byotrol product can be used as a stand alone product or as a complementary biocide additive to existing products to improve their performance in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Founded in 2005, the Company has prioritised the development of a technology that creates easier, safer and cleaner lives through partnering with providers of essential goods and services. Byotrol is the catalyst behind the aptly named global 'Hygiene Revolution'.

 

For more information, please go to www.byotrol.co.uk

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQLIFSAFLISIII
Date   Source Headline
30th Apr 20247:00 amRNSCancellation - Byotrol Plc
29th Apr 20242:15 pmRNSSecondary Trading on Asset Match
23rd Apr 20246:00 pmRNSByotrol
22nd Apr 20244:44 pmRNSCapital Reorganisation Delay
22nd Apr 20241:27 pmRNSResults of General Meeting
15th Apr 202411:48 amRNSHolding(s) in Company
8th Apr 20247:00 amRNSHolding(s) in Company
2nd Apr 20243:27 pmRNSDirector Dealing
28th Mar 20247:00 amRNSProposed Cancellation
22nd Dec 202311:44 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSHalf-year Report
14th Nov 20237:00 amRNSLaunch of PROCESSUS® Instrument Decontamination
14th Nov 20237:00 amRNSTrading Update
9th Nov 20233:43 pmRNSHolding(s) in Company
27th Sep 20237:00 amRNSBoard Changes
13th Sep 20233:33 pmRNSResult of AGM
8th Sep 20234:33 pmRNSDirector Dealing
7th Sep 20237:01 amRNSBoard Appointment
7th Sep 20237:00 amRNSTrading Update
29th Aug 20238:51 amRNSLaunch of CHEMGENE MEDLAB into human healthcare
23rd Aug 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSFinal Results
6th Jul 20237:00 amRNSPatent Grant for Novel Anti-viral Seaweed Extract
24th May 20233:14 pmRNSUS EPA approves Byotrol24 as long-lasting virucide
24th May 20238:51 amRNSDirector Dealing
28th Apr 20239:57 amRNSDirector Dealing
27th Apr 20237:00 amRNSTrading Update and Board Changes
1st Feb 20239:52 amRNSDirector Dealing
22nd Dec 20223:08 pmRNSDirector Dealing
19th Dec 202210:00 amRNSDirector Dealing
16th Dec 20227:00 amRNSGrant of Share Incentive Awards
12th Dec 20227:00 amRNSInterim results and Investor Presentation
22nd Nov 20227:00 amRNSDirectorate Changes
27th Sep 202211:15 amRNSPDMR Shareholding
22nd Sep 20225:21 pmRNSResult of AGM
8th Sep 20227:00 amRNSDirector Dealing
2nd Sep 202210:02 amRNSInvestor Presentation
30th Aug 20227:00 amRNSFinal Results
12th Aug 20223:30 pmRNSDirector Dealing
28th Jul 20227:00 amRNSCompletion of Convertible Loan Note Fundraising
11th Jul 20227:00 amRNSTrading Update and Notice of Results
22nd Apr 20229:14 amRNSHolding(s) in Company
2nd Mar 20227:00 amRNSTrading Update
12th Jan 20227:00 amRNSSenior Management Appointment
14th Dec 20219:06 amRNSSecond Price Monitoring Extn
14th Dec 20219:00 amRNSPrice Monitoring Extension
13th Dec 20217:00 amRNSDirectorate Change
9th Dec 20218:51 amRNSDirector Dealing
8th Dec 20217:00 amRNSInterim Results and Investor Presentation
2nd Nov 20217:00 amRNSDirectorate and Senior Management Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.